An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Official Title

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Summary:

The purpose of this study is to determine which combination of Nivolumab plus either Rucaparib, Docetaxel, or Enzalutamide is the most effective in treating Castration-resistant Prostate Cancer that has spread

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR)
  • Prostate-specific antigen response rate (RR-PSA)
Secondary Outcome:
  • Radiographic progression-free survival (rPFS)
  • Time to response (TTR)
  • Duration of response (DOR)
  • Time to prostate-specific antigen progression (TTP-PSA)
  • Overall Survival (OS)
  • Incidence of adverse events (AEs)
  • Incidence of serious adverse events (SAEs)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society